Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

Chromosomal deletions in AML.

Lalitha Nagarajan1

  • 1Department of Genetics, MD Anderson Cancer Center, Houston, TX, USA. lnagaraj@mdanderson.org

Cancer Treatment and Research
|March 23, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-stranded DNA-binding proteins are essential components of the architectural LDB1 protein complex.

Molecular cell·2025
Same author

Single-stranded DNA binding proteins are essential components of the architectural LDB1 protein complex.

bioRxiv : the preprint server for biology·2025
Same author

GWAS in Mice Maps Susceptibility to HIV-Associated Nephropathy to the <i>Ssbp2</i> Locus.

Journal of the American Society of Nephrology : JASN·2021
Same author

LIM-Only Protein 4 (LMO4) and LIM Domain Binding Protein 1 (LDB1) Promote Growth and Metastasis of Human Head and Neck Cancer (LMO4 and LDB1 in Head and Neck Cancer).

PloS one·2016
Same author

Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Oncotarget·2015
Same author

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Oncotarget·2015

Chromosomal deletions in acute myelogenous leukemia (AML) involve consistent overlapping regions, leading to the loss of leukemia suppressor genes. New discoveries offer hope for targeted therapies against AML.

Area of Science:

  • Hematology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Acquired, non-random chromosomal deletions are common in acute myelogenous leukemia (AML).
  • These deletions often involve unbalanced translocations, leading to the loss of critical leukemia suppressor loci.
  • While sole deletions may indicate a good prognosis, complex anomalies are linked to aggressive disease.

Purpose of the Study:

  • To identify candidate AML suppressor genes within consistently deleted regions.
  • To understand the mechanisms of gene inactivation in AML beyond the classical "two-hit" model.
  • To explore the therapeutic potential of newly discovered AML suppressor genes.

Main Methods:

  • Utilized microarray and siRNA technologies to identify candidate genes in deletion regions.

More Related Videos

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

  • Analyzed chromosomal deletions and their association with clinical outcomes.
  • Investigated gene dosage, epigenetic silencing, and uniparental disomy as mechanisms of gene inactivation.

    • Main Results:

    • Identified several candidate AML suppressor genes within critical deletion overlap regions.
    • Found that gene dosage, epigenetic silencing, and uniparental disomy are prevalent inactivation mechanisms in AML.
    • Observed that newly identified genes impact both novel and known leukemogenic pathways.

    Conclusions:

    • Recent advancements have yielded promising results in identifying leukemia suppressor genes in AML.
    • Understanding these genes and their inactivation mechanisms paves the way for targeted AML therapies.
    • Further research into mutations driving clonal evolution holds promise for treating poorly understood AML subtypes.